Stay updated on Aducanumab in Early Alzheimer's Clinical Trial
Sign up to get notified when there's something new on the Aducanumab in Early Alzheimer's Clinical Trial page.

Latest updates to the Aducanumab in Early Alzheimer's Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded Revision: v3.4.2 and removed the government funding lapse notice as well as Revision: v3.4.1.SummaryDifference0.2%

- Check20 days agoChange DetectedAdministrative updates were made to the study page: a government funding status notice was added, a new 2023 publication entry was added, a record revision labeled v3.4.1 was noted, and an earlier Erratum publication entry was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check28 days agoChange DetectedAdded Show glossary and updated revision metadata to Revision: v3.4.0; adjusted QC and FEAR Act labels (e.g., capitalization) replacing previous variants.SummaryDifference0.1%

- Check42 days agoChange DetectedThe page now shows Revision: v3.3.4, replacing Revision: v3.3.3.SummaryDifference0.0%

- Check49 days agoChange DetectedPublication details for 'Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials' were updated to include the Erratum and corrected bibliographic details. This is a bibliographic update in the Publications section and does not affect study design or results.SummaryDifference0.0%

- Check63 days agoChange DetectedExpanded the Locations section to include a comprehensive list of trial sites across multiple US states and international regions (e.g., Australia, Canada, Europe, and Asia). Several previous location groupings were removed.SummaryDifference3%

Stay in the know with updates to Aducanumab in Early Alzheimer's Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Aducanumab in Early Alzheimer's Clinical Trial page.